Orionis Biosciences

What Orionis Biosciences does

Orionis Biosciences is a clinical-stage, privately held biopharmaceutical company founded in 2015 and headquartered in Waltham, Massachusetts, with a research facility in Ghent, Belgium. The company develops precision medicines in oncology and immune disorders through three integrated proprietary technology platforms: the Allo-Glue small-molecule molecular glue platform (which induces or enhances protein-protein interactions to degrade, inhibit, modulate, or stabilize disease targets across ~20,000 human proteins); the A-Kine platform of rationally engineered, conditionally active cytokine biologics designed for selective activity on specific disease targets; and the MCE multimodal cell engager platform that creates biologics connecting immune and tumor cells. Two A-Kine candidates are in Phase 1 trials: ORB-011 (targeting cDC1 dendritic cells in solid tumors) and ORB-021 (targeting PD-L1-expressing cells to activate NK and dendritic cells while inhibiting MDSCs).

The business model is partnership-driven rather than commercial: Orionis monetizes its discovery engine through multi-year strategic co-development collaborations with large pharmaceutical companies—most prominently Novartis (initial 2020 deal, expanded June 2026 with $40M upfront and up to $1.4B in milestones) and Genentech/Roche (initial September 2023 deal with $47M upfront; second deal May 2025 with $105M upfront and up to $2B in milestones). Orionis performs discovery and lead optimization; partners assume later-stage preclinical, clinical, regulatory, and commercialization responsibility. Revenue derives from upfront payments, research/development/commercial milestones, and tiered royalties on net sales. The company has raised a disclosed $55M equity round (October 2022, led by Cormorant Asset Management with Novartis participation) on top of cumulative $192M in disclosed partnership upfronts, and is backed by academic founders at VIB-Ghent University, with strategic collaborations including MD Anderson's Project Helios. Operations span roughly 11–50 employees across US and Belgian sites, with AI/ML, custom robotics, and genome-scale chemical biology as the underlying R&D infrastructure.

Name

Orionis Biosciences

Legal name

Orionis Biosciences Inc.

Website

https://orionisbio.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Orionis Biosciences is a clinical-stage, privately held biotech operating three proximity-based drug discovery platforms—Allo-Glue molecular glues, A-Kine conditionally active cytokines, and MCE cell engagers—to develop precision cancer immunotherapies, monetized via multi-year co-development partnerships with Novartis and Genentech/Roche.

Ownership category

akta.pro rank

Product category

Biotechnology Drug Discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industry

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

Keywords

• Drug discovery platform
• Molecular glue therapeutics
• Cytokine biologics
• Precision cancer medicines
• Protein interaction mapping

Headquarters

HQ city

Waltham

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharma Partnership - Upfront Payments: Orionis receives upfront cash payments upon execution of collaboration agreements with pharmaceutical companies. These payments provide non-dilutive capital for R&D operations. Example: $40M from Novartis (2026), $105M from Genentech (2025), $47M from Genentech (2023).
2. Pharma Partnership - Milestone Payments: Orionis is eligible for research, development, and commercial milestone payments tied to achievement of predefined scientific, clinical, regulatory, and sales targets. Examples: up to $1.4B from Novartis (2026), up to $2B from Genentech (2025/2023).
3. Tiered Royalties on Net Sales: Orionis receives tiered royalties on net sales of collaboration products commercialized by pharma partners, providing recurring revenue on approved products.
4. Equity Financing: Orionis has raised equity capital from institutional investors to fund R&D and clinical advancement. Example: $55M financing round in October 2022 with participation from Cormorant Asset Management, Novartis, and other investment funds.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Orionis Biosciences discovers, designs, and engineers proximity-induced precision medicines through three proprietary platforms (Allo-Glue™ molecular glues, A-Kine® conditionally active cytokines, and MCE multimodal cell engagers) for cancer immunotherapy and immune disorders. The company operates through multi-year strategic co-development partnerships with large pharmaceutical companies (Novartis, Genentech/Roche), earning upfront payments, milestone payments, and tiered royalties on net sales. Its clinical pipeline includes two Phase 1 assets (ORB-011 and ORB-021) and multiple IND-enabling programs.

Product overview

Orionis Biosciences is a clinical-stage life sciences company with three core technology platforms: the Allo-Glue small molecule molecular glue platform, the A-Kine conditionally active cytokine biologics platform, and the MCE multimodal cell engager platform. The company operates a diversified pipeline comprising two clinical-stage programs (ORB-011 and ORB-021, both A-Kine biologics in Phase 1), multiple IND-enabling programs (ORB-GX, ORB-PR1, ORB-PR2), and discovery-stage programs (ORB-PR3). These platforms leverage proximity-induced therapeutic modalities including molecular glues, targeted cytokines, and cell engagers to address challenging cancer and immune disease targets.

Differentiator

Problem solved

Functional benefit

Brands

• Allo-Glue: Small molecule monovalent glues platform for drug discovery that induces or enhances specific protein-protein interactions to reprogram protein functions
• A-Kine
• MCE (Multimodal Cell Engagers)
• OrionisBio

Products and services

• Allo-Glue™ Platform A transformative small molecule molecular glue discovery and design platform that enables systematic, large-scale discovery of monovalent glues inducing or enhancing specific protein-protein interactions to reprogram protein functions and impact disease targets through degradation, inhibition, modulation, or stabilization. Integrates large-scale discovery across approximately 20,000 proteins (genome-scale) and hundreds of qualified ligases, custom automation, robotics, specialized numerical modeling, and AI/ML tools. Licensed to pharmaceutical partners (Novartis, Genentech/Roche) for molecular glue therapeutic discovery.
• A-Kine® Platform A next-generation immune modulator platform engineering conditionally active cytokine biologics (A-Kines) for selective activity on specific disease targets, enabling localized in-cis activation while minimizing off-target systemic toxicity. Modular plug-and-play platform with tunable targeting and effector modules across interferons, interleukins, and tumor necrosis factors. Used for development of clinical-stage candidates ORB-011 and ORB-021.
• MCE Cell Engager Platform A multimodal cell engager platform creating modular biologics that connect immune and tumor cells to deliver tailored immune responses. Features effector-less scaffolds, tunable linkers, precision targeting modules, and custom effector modules including proprietary A-Kine biologics. Supports CD8+ T cell engagers, NK cell engagers, myeloid cell engagers, and tumor cell engagers.
• ORB-011 A first-in-class A-Kine biologic designed to bind and selectively activate tumor antigen-presenting immune cells (cDC1) using a specialized on-target conditionally active interferon for cancer immunotherapy. Currently in Phase 1 for recurrent or refractory solid tumors. Orionis retains full rights.
• ORB-021 An A-Kine biologic designed to bind and selectively modulate tumor and immune cells expressing PD-L1, invoking activation of NK and dendritic cells and inhibition of myeloid derived suppressor cells (MDSCs). Currently in Phase 1 for recurrent or refractory solid tumors. Orionis retains full rights.
• ORB-GX An IND-enabling Allo-Glue compound program comprising monovalent glues targeting confidential therapeutic areas, developed in collaboration with pharma partners.
• ORB-PR1 Multiple lymphoid cell-targeting programs comprising A-Kine and cell engager approaches to elicit CD8 T and/or NK cell-mediated antitumor responses, including CD8-targeted cytokines and interleukins. Two programs in IND-enabling phase.
• ORB-PR2 Multiple myeloid cell-targeting programs including antigen-presenting cell modulators, dendritic cell engagers, and M2 macrophage/MDSC modulators designed to drive immune memory functions. Two programs in IND-enabling phase.
• ORB-PR3 Discovery-stage molecular glue and biologic programs at various optimization stages, including partnered programs with Genentech and Novartis.

Quantifiable outcome

• Two clinical-stage oncology programs (ORB-011 and ORB-021) dosed in Phase 1 studies for recurrent/refractory solid tumors
• +2 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

Partnerships

Seven partnerships are on record, tiered core, flagship and minor.

• NovartiscoreStrategic or Co-development Partner · 10 June 2026Multi-year collaboration to discover and design molecular glue drugs for challenging therapeutic targets across multiple disease areas. Orionis leverages its Allo-Glue™ platform combined with AI-driven discovery engine to accelerate target and ligase profiling and molecular glue optimization. Orionis receives $40M upfront and up to $1.4B in research, development, and commercial milestones, plus tiered royalties. This expands on an original 2020 partnership. Novartis assumes responsibility for later-stage development and commercialization. Orionis retains full rights to existing clinical candidates ORB-011 and ORB-021.
• Genentech (Roche Group)coreStrategic or Co-development Partner · 21 May 2025Second multi-year collaboration (following initial 2023 deal) to discover small-molecule monovalent glue medicines for novel and challenging oncology targets. Orionis leverages its Allo-Glue™ platform integrating chemical biology tools, engineered cellular assays, robotic automation, and AI infrastructure. Orionis receives $105M upfront and potential milestones exceeding $2B plus tiered royalties on net sales. Orionis responsible for discovery and optimization; Genentech handles later-stage preclinical, clinical development, regulatory filing, and commercialization.
• Genentech (Roche Group)coreStrategic or Co-development Partner · 20 September 2023Initial multi-year collaboration to discover novel small molecule medicines for challenging targets in major disease areas including oncology and neurodegeneration. Orionis receives $47M upfront and is eligible for milestones exceeding $2B and tiered royalties. Orionis leverages its Allo-Glue™ platform for discovery of monovalent molecular glues. This was the first Orionis-Genentech partnership, predating the 2025 expanded collaboration.
• MD Anderson Cancer CenterflagshipStrategic or Co-development Partner · 9 March 2021Project Helios: a research collaboration designed to unlock new drug development opportunities through genome-scale mapping of drug-target interactions. Combining Orionis' high-throughput drug discovery technologies with MD Anderson's expertise in small-molecule therapies and translational biology. Initial focus on oncology, with possibility of expanding to additional therapeutic areas. Aims to generate a unique dataset for machine-learning-driven drug design and illuminate the 'Drug Pocketome'.
• NovartiscoreStrategic or Co-development Partner · 5 March 2020Original four-year collaboration leveraging Orionis' Allo-Glue™ technology platform for discovery and design of novel small molecule therapeutics including protein degraders across various therapeutic areas. Terms included research funding, a convertible note investment, royalties, and potential clinical milestones. This founding partnership established Orionis' credibility with Big Pharma and provided validation of its molecular glue platform.
• VIB (Flemish Institute for Biotechnology)coreStrategic or Co-development PartnerVIB is the leading life science-focused research institute in Belgium and a founding partner of Orionis. The Cytokine Receptor Laboratory at VIB-Ghent University, led by co-founder Jan Tavernier, is central to Orionis' scientific foundation. Griet Vanpoucke, Head of New Ventures at VIB, serves on Orionis' Board of Directors. VIB translational infrastructure underpins Orionis' biologics platform development.
• Harvard UniversityminorStrategic or Co-development PartnerAcademic collaboration partner listed on Orionis' partnerships page. Nature and scope of collaboration not further detailed in available source materials.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Amphista Therapeutics: Private UK-based developer of small-molecule targeted protein degraders with multiple Big Pharma partnerships. Comparable to Orionis in induced-proximity modality and discovery-platform business model, but pre-clinical stage.
• Triana Biomedicines: Private molecular glue discovery company focused on oncology and other diseases. Closely comparable to Orionis's Allo-Glue monovalent glue approach and partnership-led business model, though narrower in scope and pipeline maturity.
• Neomorph: Private targeted protein degradation company (co-founded by Amgen and Dana-Farber) developing molecular glues against undruggable oncology targets. Comparable to Orionis in induced-proximity mechanism and early-stage discovery platform positioning.

Direct peers

• Nurix Therapeutics: Clinical-stage targeted protein degradation company using ligase-modulating drugs and degrader antibody conjugates (DACs) for oncology and immunology. Highly comparable to Orionis's Allo-Glue platform in proximity-based mechanism and Big Pharma deal structure (Sanofi, Gilead, Pfizer).
• C4 Therapeutics: Developer of small-molecule degraders (PROTACs and molecular glues) for oncology and other diseases, with active partnerships including Biogen, Roche, and Calithera. Comparable to Orionis in induced-proximity mechanism and pharma partnership GTM.
• Kymera Therapeutics: Clinical-stage targeted protein degradation company developing heterobifunctional degraders and molecular glues across immunology and oncology. Comparable platform breadth, partnership model (with Sanofi), and pipeline stage to Orionis's Allo-Glue and A-Kine programs.
• Monte Rosa Therapeutics: Clinical-stage biotech developing molecular glue degraders focused on immunology and oncology indications via cereblon- and non-cereblon-based ligases. Closely comparable to Orionis in induced-proximity mechanism, small-molecule glue modality, and pipeline composition across immune-related diseases.
• Werewolf Therapeutics: Clinical-stage biotech developing conditionally activated cytokine-based PREDATOR™ therapeutics designed to be activated selectively in the tumor microenvironment. Direct functional analog to Orionis's A-Kine conditionally active cytokine platform, both targeting systemic-toxicity reduction in cytokine therapy.
• Arvinas: Pioneering targeted protein degradation company using small-molecule PROTAC and molecular glue degraders against historically undruggable oncology and neuroscience targets. Most direct peer to Orionis's Allo-Glue monovalent glue platform in modality, target class, and partnership-driven business model.

Others

• FORMA Therapeutics: Predecessor company of CEO Niko Kley, acquired by Novo Nordisk in 2022; developed small-molecule therapies for cancer and rare diseases including proximity-based agents. Closely related through founder pedigree and shared proximity-biology heritage rather than direct competition.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/orionis-biosciences

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds7 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Orionis Biosciences